Fulcrum Therapeutics (FULC) is having a rough week. On Monday, the company announced it was pulling the plug on pociredir, its lead experimental drug for sickle cell disease, after the Food and Drug Administration raised serious safety concerns. The stock initially cratered but has since recovered a bit — shares were up about 2% on Thursday to around $3.29, though that's still dangerously close to the 52-week low of $2.83.

The problem? The FDA is worried that pociredir, which targets a protein called EED in the PRC2 complex, could cause secondary hematologic malignancies — basically, cancers that develop as a side effect of treatment. Those fears were amplified by the experience of another drug, Tazverik (tazemetostat), which targets a different part of the same complex (EZH2) and was pulled from the global market in March 2026 after showing an unexpectedly high rate of these cancers.

Fulcrum tried to argue that pociredir was different. The company submitted data to the FDA suggesting that the mechanistic differences between targeting EED versus EZH2 — which play distinct biological roles — should matter for the risk assessment. But the FDA wasn't buying it. The agency concluded that any drug that messes with the PRC2 complex carries the same malignancy risk, regardless of which specific subunit it targets. And given that pociredir had already shown some preclinical malignancy signals, there was no viable regulatory path forward.

So Fulcrum is now left with a big hole in its pipeline and a stock that's down more than 50% from its 20-day moving average. The company is launching a strategic review to explore options, which could include a merger or acquisition. In biotech speak, that often means "we're putting a 'for sale' sign up."

Technical Picture: Oversold but Still Bearish

From a technical standpoint, things look grim. The stock is trading at $3.17, well below its 20-day simple moving average of $6.38 and its 50-day SMA of $7.08. That's a 55% discount to the 50-day average, which is a pretty clear sign of bearish momentum. The Relative Strength Index (RSI) is at 20.43, which is deep in oversold territory — typically that suggests a bounce could be coming, but it's not guaranteed when the fundamental story is this ugly.

Key resistance sits at $6.38 (the 20-day SMA), while support is at $2.83, near the 52-week low. If the stock breaks below that, it could get ugly.

Analysts Throw in the Towel

Wall Street has responded with a flurry of downgrades. JP Morgan cut its rating to Underweight on June 3. Stifel and Piper Sandler both downgraded to Underweight on June 2, with price targets slashed to $3.00. The consensus rating is now Hold, with an average price target of $8.67 — but that average is likely to fall further as more analysts update their models.

For now, Fulcrum is a company in limbo. The strategic review could lead to a sale, but with the lead drug dead and the pipeline thin, the bargaining power isn't great. Investors are left waiting to see if a white knight emerges — or if the stock drifts toward that $2.83 floor.